Özet:

Introduction: Breast cancer is a heterogeneous disease and it encompasses a variety of entities with distinct morphological appearances and clinical behaviors. In recent years, it has become evident that this diversity is the result of genetic alterations. Molecular profiling has provided biological evidence for heterogeneity of breast cancer through the identification of intrinsic subtypes. Triple negative breast cancer (TNBC) is the subtype of breast cancer that does not over express human epidermal growth factor 2 receptors (HER2), while also lacking expression of estrogen receptors (ER) and progesterone receptors (PR).Materials and Methods: All cases with biopsy proven breast cancer will be evaluated. The time period of the study is from January 2018 to January 2020. The receptor status will be evaluated by immunohistochemistry (IHC) and divided into TNBC and non-TNBC. The patients in both the groups will be given appropriate treatment based on their oncological stage. Results: Most of the patient’s age was between 4th to 6thdecade. The youngest patient in our study was 26 yrs old. The oldest patient in our study was 75 yrs. The highest incidence of breast cancers was in the 4th decade of life with 53 patients corresponding to 32.12% of patients. Majority of the breast cancers were of the infiltrating duct cell carcinoma not otherwise specified type (IDCC-NOS). Other variants such as medullary, mucinous, and lobular were encountered infrequently.Conclusion: Triple negative breast cancer is not an uncommon subtype in our region. It is more prevalent than western population. Triple negative breast cancer affects younger population with a median age of 46.25 yr in the current study. Triple negative breast cancer presents at a more advanced stage with most tumors being clinically palpable and the most common presentation being lump in breast .It has good response to neoadjuvant chemotherapy.

Anahtar Kelimeler: